Andrew S Brohl1, Jeffrey R Stinson2, Helen C Su3, Thomas Badgett4, Chester D Jennings5, Gauthaman Sukumar6, Sivasish Sindiri1, Wei Wang7, Lela Kardava7, Susan Moir7, Clifton L Dalgard6, Jeffrey A Moscow4, Javed Khan8, Andrew L Snow9. 1. Oncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 2016B, Bethesda, MD, 20892, USA. 2. Department of Pharmacology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814, USA. 3. Laboratory of Host Defenses, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA. 4. Department of Pediatrics and Markey Cancer Center, College of Medicine, University of Kentucky, Lexington, KY, USA. 5. Department of Pathology, College of Medicine, University of Kentucky, Lexington, KY, USA. 6. Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 7. Immunopathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA. 8. Oncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Building 37, Room 2016B, Bethesda, MD, 20892, USA. khanjav@mail.nih.gov. 9. Department of Pharmacology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd., Bethesda, MD, 20814, USA. andrew.snow@usuhs.edu.
Abstract
PURPOSE: Activating germline mutations in CARD11 have recently been linked to a rare genetic disorder associated with congenital B cell lymphocytosis. We describe a patient with a similar clinical phenotype who had a de novo germline G123D CARD11 mutation. METHODS: Whole exome sequencing was performed on DNA from the patient and his biological parents. Laboratory studies examined characteristics of the patient's B and T lymphocytes. A CARD11 cDNA containing the mutation was transfected into a lymphocyte cell line to gain an understanding of its function. RNA sequencing was performed on samples from the patient and from patients with alternate germline CARD11 mutations and differential gene expression analysis was performed. RESULTS: The patient had a decade-long history of severe polyclonal B lymphocytosis in the 20,000-90,000 lymphocytes/mm(3) range, which was markedly exacerbated by EBV infection and splenectomy at different times. He had a heterozygous germline CARD11 mutation causing a G123D amino acid substitution, which was demonstrated to induce NF-κB activation in unstimulated lymphocytes. In contrast to previous patients with CARD11 mutations, this patient's B cells exhibited higher expression of several cell cycle progression genes, as well as enhanced proliferation and improved survival following B cell receptor stimulation. CONCLUSIONS: This is the third reported germline and first de novo CARD11 mutation shown to cause congenital B cell lymphocytosis. The mutation was associated with a dramatically greater lymphocytosis than in previously described cases, disproportionate to the level of constitutive NF-κB activation. However, comparative review of the patient's clinical history, combined with additional genomic and functional analyses, underscore other important variables that may affect pathophysiology or regulate mutant CARD11 function in B cell proliferation and disease. We now refer to these patients as having BENTA disease (B cell Expansion with NF-κB and T cell Anergy).
PURPOSE: Activating germline mutations in CARD11 have recently been linked to a rare genetic disorder associated with congenital B cell lymphocytosis. We describe a patient with a similar clinical phenotype who had a de novo germline G123DCARD11 mutation. METHODS: Whole exome sequencing was performed on DNA from the patient and his biological parents. Laboratory studies examined characteristics of the patient's B and T lymphocytes. A CARD11 cDNA containing the mutation was transfected into a lymphocyte cell line to gain an understanding of its function. RNA sequencing was performed on samples from the patient and from patients with alternate germline CARD11 mutations and differential gene expression analysis was performed. RESULTS: The patient had a decade-long history of severe polyclonal B lymphocytosis in the 20,000-90,000 lymphocytes/mm(3) range, which was markedly exacerbated by EBV infection and splenectomy at different times. He had a heterozygous germline CARD11 mutation causing a G123D amino acid substitution, which was demonstrated to induce NF-κB activation in unstimulated lymphocytes. In contrast to previous patients with CARD11 mutations, this patient's B cells exhibited higher expression of several cell cycle progression genes, as well as enhanced proliferation and improved survival following B cell receptor stimulation. CONCLUSIONS: This is the third reported germline and first de novo CARD11 mutation shown to cause congenital B cell lymphocytosis. The mutation was associated with a dramatically greater lymphocytosis than in previously described cases, disproportionate to the level of constitutive NF-κB activation. However, comparative review of the patient's clinical history, combined with additional genomic and functional analyses, underscore other important variables that may affect pathophysiology or regulate mutant CARD11 function in B cell proliferation and disease. We now refer to these patients as having BENTA disease (B cell Expansion with NF-κB and T cell Anergy).
Authors: Z J Liu; T Ueda; T Miyazaki; N Tanaka; S Mine; Y Tanaka; T Taniguchi; H Yamamura; Y Minami Journal: Mol Cell Biol Date: 1998-06 Impact factor: 4.272
Authors: Rachel Ettinger; Gary P Sims; Anna-Marie Fairhurst; Rachel Robbins; Yong Sing da Silva; Rosanne Spolski; Warren J Leonard; Peter E Lipsky Journal: J Immunol Date: 2005-12-15 Impact factor: 5.422
Authors: Johann Greil; Tobias Rausch; Thomas Giese; Obul R Bandapalli; Volker Daniel; Isabelle Bekeredjian-Ding; Adrian M Stütz; Christoph Drees; Susanne Roth; Jürgen Ruland; Jan O Korbel; Andreas E Kulozik Journal: J Allergy Clin Immunol Date: 2013-04-03 Impact factor: 10.793
Authors: Yogesh S Jeelall; James Q Wang; Hsei-Di Law; Heather Domaschenz; Herman K H Fung; Axel Kallies; Stephen L Nutt; Christopher C Goodnow; Keisuke Horikawa Journal: J Exp Med Date: 2012-10-01 Impact factor: 14.307
Authors: Ryan D Morin; Maria Mendez-Lago; Andrew J Mungall; Rodrigo Goya; Karen L Mungall; Richard D Corbett; Nathalie A Johnson; Tesa M Severson; Readman Chiu; Matthew Field; Shaun Jackman; Martin Krzywinski; David W Scott; Diane L Trinh; Jessica Tamura-Wells; Sa Li; Marlo R Firme; Sanja Rogic; Malachi Griffith; Susanna Chan; Oleksandr Yakovenko; Irmtraud M Meyer; Eric Y Zhao; Duane Smailus; Michelle Moksa; Suganthi Chittaranjan; Lisa Rimsza; Angela Brooks-Wilson; John J Spinelli; Susana Ben-Neriah; Barbara Meissner; Bruce Woolcock; Merrill Boyle; Helen McDonald; Angela Tam; Yongjun Zhao; Allen Delaney; Thomas Zeng; Kane Tse; Yaron Butterfield; Inanç Birol; Rob Holt; Jacqueline Schein; Douglas E Horsman; Richard Moore; Steven J M Jones; Joseph M Connors; Martin Hirst; Randy D Gascoyne; Marco A Marra Journal: Nature Date: 2011-07-27 Impact factor: 49.962
Authors: Andrew L Snow; Wenming Xiao; Jeffrey R Stinson; Wei Lu; Benjamin Chaigne-Delalande; Lixin Zheng; Stefania Pittaluga; Helen F Matthews; Roland Schmitz; Sameer Jhavar; Stefan Kuchen; Lela Kardava; Wei Wang; Ian T Lamborn; Huie Jing; Mark Raffeld; Susan Moir; Thomas A Fleisher; Louis M Staudt; Helen C Su; Michael J Lenardo Journal: J Exp Med Date: 2012-11-05 Impact factor: 14.307
Authors: Jeffrey R Stinson; Batsukh Dorjbal; Dennis P McDaniel; Liron David; Hao Wu; Andrew L Snow Journal: Cell Immunol Date: 2020-05-14 Impact factor: 4.868
Authors: Zhaoquan Wang; Shelby M Hutcherson; Chao Yang; Rakhi P Jattani; Julia M Tritapoe; Yong-Kang Yang; Joel L Pomerantz Journal: J Biol Chem Date: 2019-08-07 Impact factor: 5.157
Authors: Batsukh Dorjbal; Jeffrey R Stinson; Chi A Ma; Michael A Weinreich; Bahar Miraghazadeh; Julia M Hartberger; Stefanie Frey-Jakobs; Stephan Weidinger; Lena Moebus; Andre Franke; Alejandro A Schäffer; Alla Bulashevska; Sebastian Fuchs; Stephan Ehl; Sandhya Limaye; Peter D Arkwright; Tracy A Briggs; Claire Langley; Claire Bethune; Andrew F Whyte; Hana Alachkar; Sergey Nejentsev; Thomas DiMaggio; Celeste G Nelson; Kelly D Stone; Martha Nason; Erica H Brittain; Andrew J Oler; Daniel P Veltri; T Ronan Leahy; Niall Conlon; Maria C Poli; Arturo Borzutzky; Jeffrey I Cohen; Joie Davis; Michele P Lambert; Neil Romberg; Kathleen E Sullivan; Kenneth Paris; Alexandra F Freeman; Laura Lucas; Shanmuganathan Chandrakasan; Sinisa Savic; Sophie Hambleton; Smita Y Patel; Michael B Jordan; Amy Theos; Jeffrey Lebensburger; T Prescott Atkinson; Troy R Torgerson; Ivan K Chinn; Joshua D Milner; Bodo Grimbacher; Matthew C Cook; Andrew L Snow Journal: J Allergy Clin Immunol Date: 2018-08-28 Impact factor: 10.793